Dr. Friedlander on Checkpoint Inhibitors in the Second-Line Setting of Bladder Cancer

Terence Friedlander, MD
Published: Wednesday, Nov 29, 2017



Terence Friedlander, MD, an assistant clinical professor in the Division of Hematology/Oncology, Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, discusses checkpoint inhibitors in the second-line setting for patients with bladder cancer.

The cleanest data is for pembrolizumab (Keytruda) from the KEYNOTE-045 study because there was an overall survival (OS) benefit independent of PD-L1 expression, explains Friedlander.

According to Friedlander, there is rationale to give atezolizumab (Tecentriq) in this setting when looking at the intent-to-treat population.
 
SELECTED
LANGUAGE


Terence Friedlander, MD, an assistant clinical professor in the Division of Hematology/Oncology, Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, discusses checkpoint inhibitors in the second-line setting for patients with bladder cancer.

The cleanest data is for pembrolizumab (Keytruda) from the KEYNOTE-045 study because there was an overall survival (OS) benefit independent of PD-L1 expression, explains Friedlander.

According to Friedlander, there is rationale to give atezolizumab (Tecentriq) in this setting when looking at the intent-to-treat population.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Archived Version of a Live Webcast: Virtual Current Trends™: European Perspectives on the Advancing Role of CAR T-Cell Therapy in Hematologic MalignanciesJun 29, 20192.0
Community Practice Connections™: Practical Application of Sequencing for EGFR-Mutant Lung Cancers: A Focus on Recent Evidence and Key Next Steps in TrialsJun 29, 20192.5
Publication Bottom Border
Border Publication
x